

Miguel Gallardo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4167241/publications.pdf>

Version: 2024-02-01

39
papers

602
citations

623574

14
h-index

610775

24
g-index

39
all docs

39
docs citations

39
times ranked

1259
citing authors

#	ARTICLE	IF	CITATIONS
1	hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies. <i>Cancer Cell</i> , 2015, 28, 486-499.	7.7	110
2	Aberrant hnRNP K expression: All roads lead to cancer. <i>Cell Cycle</i> , 2016, 15, 1552-1557.	1.3	74
3	High Resolution Melting Analysis for JAK2 Exon 14 and Exon 12 Mutations. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 155-161.	1.2	48
4	GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy. <i>Frontiers in Immunology</i> , 2019, 10, 2361.	2.2	45
5	Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases. <i>Annals of Hematology</i> , 2008, 87, 741-749.	0.8	43
6	A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 288-296.	1.7	36
7	A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 6035-6046.	2.9	29
8	MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia. <i>Scientific Reports</i> , 2019, 9, 18630.	1.6	24
9	Uncovering the Role of RNA-Binding Protein hnRNP K in B-Cell Lymphomas. <i>Journal of the National Cancer Institute</i> , 2020, 112, 95-106.	3.0	22
10	Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation. <i>Journal of Clinical Pathology</i> , 2011, 64, 1010-1013.	1.0	20
11	Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera. <i>Molecular Cancer</i> , 2013, 12, 142.	7.9	20
12	Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm. <i>British Journal of Haematology</i> , 2013, 161, 667-676.	1.2	20
13	Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms. <i>Haematologica</i> , 2017, 102, 2048-2057.	1.7	18
14	Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse. <i>Haematologica</i> , 2021, 106, 2325-2333.	1.7	18
15	p53-independent ibrutinib responses in an E μ 1/4-TCL1 mouse model demonstrates efficacy in high-risk CLL. <i>Blood Cancer Journal</i> , 2016, 6, e434-e434.	2.8	10
16	Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma. <i>Cancers</i> , 2021, 13, 1662.	1.7	10
17	Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness. <i>Blood</i> , 2019, 134, 836-840.	0.6	9
18	Proteomic Analysis Identifies HSP70 As a Novel Target Therapy to Polycythemia Vera. <i>Blood</i> , 2011, 118, 2827-2827.	0.6	9

#	ARTICLE	IF	CITATIONS
19	Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia. <i>Annals of Hematology</i> , 2011, 90, 939-946.	0.8	7
20	Microengineering double layer hydrogel structures towards the recapitulation of the hematopoietic stem cell niche. <i>Science Bulletin</i> , 2018, 63, 1319-1323.	4.3	5
21	Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms. <i>Haematologica</i> , 2019, 104, 937-946.	1.7	5
22	Droplet Microfluidics for the ex Vivo Expansion of Human Primary Multiple Myeloma Cells. <i>Micromachines</i> , 2020, 11, 261.	1.4	5
23	Long-Term Human Hematopoietic Stem Cell Culture in Microdroplets. <i>Micromachines</i> , 2021, 12, 90.	1.4	5
24	The E μ -hnRNP K Murine Model of Lymphoma: Novel Insights into the Role of hnRNP K in B-Cell Malignancies. <i>Frontiers in Immunology</i> , 2021, 12, 634584.	2.2	3
25	Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 3189.	1.7	3
26	hnRNP K Overexpression Drives AML Progression By Altering Pathways Critical for Myeloid Proliferation and Differentiation. <i>Blood</i> , 2016, 128, 744-744.	0.6	3
27	Combination Therapy with BTK Inhibitor Plus Anti-PD-1 Antibody Results in a Hyperprogressor Phenotype in a Mouse Model of CLL. <i>Blood</i> , 2018, 132, 4416-4416.	0.6	1
28	PF250 HNRNP K OVEREXPRESSION INDUCE NUCLEOLAR STRESS, A HALLMARK OF ACUTE MYELOID LEUKEMIA. <i>HemaSphere</i> , 2019, 3, 76-77.	1.2	0
29	Importance of JAK2 V617F Allele Burden in the Diagnosis of Myeloproliferative Diseases and Its Association to Age.. <i>Blood</i> , 2007, 110, 4654-4654.	0.6	0
30	Metalloproteases Could Be Involved in Erythroid Differentiation in MPN. <i>Blood</i> , 2011, 118, 5161-5161.	0.6	0
31	Inhibition of Related JAK/STAT Pathways with Molecular Targeted Drugs Shows Strong Synergy with Ruxolitinib in Chronic Myeloproliferative Neoplasms. <i>Blood</i> , 2012, 120, 5054-5054.	0.6	0
32	BET Bromodomain Inhibition Reduces Leukemic Burden and Prolongs Survival In The E μ /4-TCL1 Transgenic Mouse Model Of Chronic Lymphocytic Leukemia (CLL) Independent Of TP53 Mutation Status. <i>Blood</i> , 2013, 122, 876-876.	0.6	0
33	hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21.32 Locus That Defines a Subset of AML. <i>Blood</i> , 2015, 126, 439-439.	0.6	0
34	hnRNP K: A Regulator of Global Transcription and Translation That Drives Lymphomagenesis. <i>Blood</i> , 2018, 132, 1346-1346.	0.6	0
35	hnRNP K Overexpression Drives Myeloid Malignancy Via Interaction with RUNX1. <i>Blood</i> , 2018, 132, 2622-2622.	0.6	0
36	S846 HNRNP K LEVELS PREDICT FOR POOR CLINICAL RESPONSES IN DLBCL AND REPRESENT A NOVEL THERAPEUTIC TARGET. <i>HemaSphere</i> , 2019, 3, 377-378.	1.2	0

#	ARTICLE	IF	CITATIONS
37	PF566 INCREASE OF MITOCHONDRIAL ACTIVITY CONTRIBUTES TO RELAPSE IN MULTIPLE MYELOMA, A NOVEL THERAPEUTIC OPPORTUNITY. HemaSphere, 2019, 3, 235-236.	1.2	0
38	PF224ÂNOVEL ICMT INHIBITOR AS POTENTIAL TREATMENT OF RASâ€DRIVEN ACUTE MYELOID LEUKEMIA. HemaSphere, 2019, 3, 64-65.	1.2	0
39	PS1357 FITNESS SIGNATURES IN MULTIPLE MYELOMA PROGRESSION AND RESISTANCE. HemaSphere, 2019, 3, 620.	1.2	0